MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does MindBio Therapeutics Corp. (MBIO) operate in?
MindBio Therapeutics Corp. belongs to the Other sector and operates in the Biotechnology industry.
What is MindBio Therapeutics Corp. (MBIO) current stock price?
As of the latest data, MindBio Therapeutics Corp. stock price is CA$0.21, with a previous close of CA$0.20. MindBio Therapeutics Corp. gained CA$0.01 in the last trading session, representing a 5% increase.
What is MindBio Therapeutics Corp. (MBIO) current market capitalization?
MindBio Therapeutics Corp. market cap is approximately 1.53 million.
What is MindBio Therapeutics Corp. (MBIO) Earnings Per Share (EPS)?
The trailing EPS is -CA$1.67.
Does MindBio Therapeutics Corp. (MBIO) pay dividends?
No. MindBio Therapeutics Corp. does not pay a dividend.
What is MindBio Therapeutics Corp. (MBIO) beta (volatility) score?
MindBio Therapeutics Corp. has a beta of -1.294, indicating lower volatility than the overall market.
